The treatment of urinary tract infections and use of ciprofloxacin extended release

Expert Opinion on Investigational Drugs

Volumn 15, Issue 5, 2006, Pages 519-532

  Hickerson, Adam D ^a   Carson, Culley C ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Ciprofloxacin ER; Ciprofloxacin IR; Extended release; UTIs

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; THEOPHYLLINE; TIZANIDINE; WARFARIN;

ACUTE PYELONEPHRITIS; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ERADICATION THERAPY; ESCHERICHIA COLI; HEART ARRHYTHMIA; HUMAN; INTERSTITIAL PNEUMONIA; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PHARMACODYNAMICS; QT PROLONGATION; SUSTAINED RELEASE FORMULATION; TENDINITIS; TENDON RUPTURE; TREATMENT FAILURE; URINARY TRACT INFECTION; UROLITHIASIS; VOMITING;

ANTI-INFECTIVE AGENTS, URINARY; CIPROFLOXACIN; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; URINARY TRACT INFECTIONS;

EID: 33646465540     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.5.519     Document Type: Article

References (78)

1. FOXMAN B: Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. (2002) 8:113 (Suppl. IA:5S-13S).
2. SCHAPPERT SM: Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1997. Vital Health Statistics 13. (1999) 143(i-iv): 1-39.
3. SCHAEFFER A: Walsh: Campbell's Urology. 8th Edition, Section 4, Chapter 14 (2002) 1:516-517.
4. McLAUGHLIN SP, CARSON CC: Urinary tract infections in women. Med. Clin. North Am. (2004) 88(2):417-429.
5. STAPLETON A, STAMM WE: Prevention of urinary tract infection. Infect. Dis. Clin. North Am. (1997) 11(3):719-733.
6. RONALD A: The etiology of urinary tract infection: traditional and emerging pathogens. Dis. Mon. (2003) 49(2):71-82.
7. RONALD A: The etiology of urinary tract infection: traditional and emerging pathogens. Am. J. Med. (2002) 113(Suppl. 1A):14S-19S.
8. BRUMFITT W, HAMILTON-MILLER JM: A review of the problem of urinary infection management and the evaluation of a potential new antibiotic. J. Antimicrob. Chemother. (1984) 13(Suppl. B):121-133.
9. MABECK CE: Treatment of uncomplicated urinary tract infection in non-pregnant women. Postgrad. Med. J. (1972) 48(556):69-75.
10. RICHARDS D, TOOP L, CHAMBERS S, FLETCHER L: Response to antibiotics of women with symptoms of urinary tract infection but negative dipstick urine test results: double blind randomised controlled trial. Br. Med. J. (2005) 331(7509):143.
11. FOXMAN B, FRERICHS RR: Epidemiology of urinary tract infection: I. Diaphragm use and sexual intercourse. Am. J. Public Health (1985) 75(11):1308-1313.
12. ERNST EJ, ERNST ME, HOEHNS JD, BERGUS GR: Women's quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health Qual. Life Outcomes (2005) 3(1):45.
13. GRUDE N, TVETEN Y, JENKINS A, KRISTIANSEN BE: Uncomplicated urinary tract infections. Bacteria] findings and efficacy of empirical antibacterial treatment. Scand. J. Prim. Health Care (2005) 23(2):115-119.
14. GUPTA K, HOOTON TM, STAMM WE: Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Intern. Med. (2001) 135(1):41-50.
15. PERFETTO EM, KEATING K, MERCHANTS, NICHOLS BR: Acute uncomplicated UTI and E. coli resistance: implications for first-line empirical antibiotic therapy. J Manag. Care Pharm. (2004) 10(1):17-25.
16. WARREN JW, ABRUTYN E, HEBEL JR, JOHNSON JR, SCHAEFFER AJ, STAMM WE: Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin. Infect. Dis. (1999) 29(4):745-758.
17. NABER KG, BERGMAN B, BISHOP MC et al: EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur. UroL (2001) 40(5):576-588.
18. McCARTY JM, RICHARD G, HUCK W et al: A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. Am. J Med. (1999) 106(3):292-299.
19. GUPTA K, HOOTON TM, ROBERTS PL, STAMM WE: Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Ann. Intern. Med. (2001) 135(1)9-16.
20. SVANBORG C, GODALY G: Bacterial virulence in urinary tract infection. Infect. Dis. Clin. North Am. (1997) 11(3):513-529.
21. TALAN DA, STAMM WE, HOOTON TM et al: Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. J. Am. Med. Assoc. (2000) 283(12):1583-1590.
22. COX CE, MARBURY TC, PITTMAN WG et al.: A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin. Ther. (2002) 24(2):223-236.
23. TALAN DA, KLIMBERG IW, NICOLLE LE, SONG J, KOWALSKY SF, CHURCH DA: Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J. Urol. (2004) 171(2 Part 1):734-739.
24. STEINKE DT, SEATON RA, PHILLIPS G, MacDONALD TM, DAVEY PG: Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. J. Antimicrob. Chemother. (2001) 47(6):781-787.
25. WRIGHT SW. WRENN KD, HAYNES ML: Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J. Gen. Intern. Med. (1999) 14(10):606-609.
26. CHRISTIAENS TC, DIGRANES A, BAERHEIM A: The relation between sale of antimicrobial drugs and antibiotic resistance in uropathogens in general practice. Scand. J. Prim. Health Care (2002) 20(1):45-49.
27. KARLOWSKY JA, KELLY LJ, THORNSBERRY C, JONES ME, SAHM DF: Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob. Agents Chemother. (2002) 46(8):2540-2545.
28. KARLOWSKY JA, KELLY LJ, THORNSBERRY C et al.: Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking resistance in the United States today. The Surveillance Network. Int. J. Antimicrob. Agents (2002) 19(1):21-31.
29. DAVID RD, DE BLIEUX PM, PRESS R: Rational antibiotic treatment of outpatient genitourinary infections in a changing environment. Am. J. Med. (2005) 118(Suppl. 7A):7S-13S.
30. ZHANEL GG, KARLOWSKY JA, HARDING GK et al: A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimerhoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob. Agents Chemother. (2000) 44(4):1089-1092.
31. GORDON KA, JONES RN: SENTRY Participant Groups (Europe, Latin America, North America). Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol Infect. Dis. (2003) 45(4):295-301.
32. CHEUNG TK, CHU YW, CHU MY, MA CH, YUNG RW, KAM KM: Plasmid-mediated resistance to ciprofloxacin and cefotaxime in clinical isolates of Salmonella enterica serotype Enteritidis in Hong Kong. J. Antimicrob. Chemother. (2005) 56(3):586-589.
33. CHEN FJ, LAUDERDALE TL, McDONALD LC et al: Molecular epidemiology of emerging reduced susceptibility to fluoroquinolones in Escherichia coli. J. Med. Microbiol. (2004) 53(Part 1):85-86.
34. CHEN FJ, LO HJ: Molecular mechanisms of fluoroquinolone resistance. J. Microbiol. Immunol. Infect. (2003) 36(1):1-9.
35. TRAN JH, JACOBY GA, HOOPER DC: Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob. Agents Chemother. (2005) 49(7):3050-3052.
36. KOMP LINDGREN P, KARLSSON A, HUGHES D: Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob. Agents Chemother. (2003) 47(10):3222-3232.
37. VAN BAMBEKE F, MICHOT JM, VAN ELDERE J, TULKENS PM: Quinolones in 2005: an update. Clin. Microbiol. Infect. (2005) 11(4):256-280. (Erratum in: Clin. Microbiol. Infect. (2005) 11(6):513.)
38. MARCUSSON LL, OLOFSSON SK, KOMP LINDGREN P, CARS O, HUGHES D: Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J. Antimicrob. Chemother. (2005) 55(6):938-943.
39. WAGENLEHNER FM, WEIDNER W, NABER KG: Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/ pharmacodynamic considerations. J. Hosp. Infect. (2005) 60(3):191-200.
40. SAHM DF, THORNSBERRY C, FIELD DC, JONES ME, KARLOWSKY JA: Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000. Antimicrob. Agents Chemother. (2001) 45(5):1402-1406.
41. GALES AC, JONES RN, GORDON KA et al.: Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998). J. Antimicrob. Chemother. (2000) 45(3):295-303.
42. GUPTA K, HOOTON TM, STAMM WE: Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J. Antimicrob. Chemother. (2005) 56(1):243-246.
43. KARACA Y, COPLU N, GOZALAN A, ONCUL O, CITIL BE, ESEN B: Co-trimoxazole and quitiolone resistance in Escherichia coli isolated from urinary tract infections over the last 10 years. Int. J. Antimicrob. Agents (2005) 26(1):75-77.
44. KURUTEPE S, SURUCUOGLU S, SEZGIN C, GAZI H, GULAY M, OZBAKKALOGLU B: Increasing antimicrobial resistance in Escherichia coli isolates from community-acquired urinary tract infections during 1998-2003 in Manisa, Turkey. Jpn J. Infect. Dis. (2005) 58(3):159-161.
45. OTEO J, LAZARO E, DE ABAJO FJ, BAQUERO F, CAMPOS J: Spanish members of EARSS. Antimicrobial-resistant invasive Escherichia coli, Spain. Emerg. Infect Dis. (2005) 11(4):546-553.
46. ALOS JI, SERRANO MG, GOMEZ-GARCES JL, PERIANES J: Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data. Clin. Microbiol. Infect. (2005) 11(3):199-203.
47. ISHIKAWA K, HAYAKAWA S, MIYAKAWA S, KUSAKA M, SHIROKI R, HOSHINAGA K: Survey of the susceptibility of urinary isolates to antibacterial agents in 2003. J. Infect. Chemother. (2005) 11(1):44-47.
48. MURATANI T, MATSUMOTO T: Bacterial resistance to antimicrobials in urinary isolates. Int. J. Antimicrob. Agents (2004) 24(Suppl. 1):S28-S31.
49. MAHAMAT A, LAVIGNE JP, FABBRO-PERAY P, KINOWSKI JM, DAURES JP, SOTTO A: Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model. Clin. Microbiol. Infect. (2005) 11(4)301-306.
50. ARSLAN H, AZAP OK, ERGONUL O, TIMURKAYNAK F: Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J. Antimicrob. Chemother. (2005) 56(5):914-918.
51. SABIR N, KHAN E, SHEIKH L, HASAN R: Impact of antibiotic usage on resistance in microorganisms; urinary tract infections with E. coli as a case in point. J. Pak. Med. Assoc. (2004) 54(9):472-475.
52. HOOTON TM: Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int. J. Antimicrob. Agents (2003) 22(Suppl. 2):65-72.
53. KILLGORE KM, MARCH KL, GUGLIELMO BJ: Risk factors for communiry-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann. Pharmacother. (2004) 38(7-8):1148-1152.
54. STELLING JM, TRAVERS K, JONES RN, TURNER PJ, O'BRIEN TF, LEVY SB: Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. Emerg. Infect. Dis. (2005) 11(6):873-882.
55. MASTERTON RG, BOCHSLER JA: High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J. Antimicrob. Chemother. (1995) 35(1):129-137.
56. RAZ R, CHAZAN B, KENNES Y et al.: Israeli Urinary Tract Infection Group. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP - SMX-resistant uropathogens. Clin. Infect. Dis. (2002) 34(9):1165-1169.
57. BERGAN T. Extravascular penetration of ciprofloxacin. A review. Diagn. Microbiol. Infect. Dis. (1990) 13(2):103-114.
58. STASS H, NAGELSCHMITZ J, BRENDEL E et al: The effect of food on the pharmacokinetics of a new ciprofloxacin once daily formulation for the treatment of uncomplicated and complicated urinary tract infections. J. Investig. Med. (2002) 50:154A (Abstract 24).
59. STASS H, NAGELSCHMITZ J, BRENDEL E et al: Pharmacokinetic characterization of a new ciprofloxacin once daily for treatment of uncomplicated urinary tract infections. J. Investig. Med. (2002) 50:154A (Abstract 25).
60. STASS H, NAGELSCHMITZ J, BRENDEL E et al.: Pharmacokinetics of a new ciprofloxacin once daily formulation for the treatment of complicated urinary tract infections. J. Investig. Med. (2002) 50:154A (Abstract 23).
61. FOURCROY JL, BERNER B, CHIANG YK, CRAMER M, ROWE L, SHORE N: Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob. Agents Chemother. (2005) 49(10):4137-4143.
62. STRATTON C: Fluoroquinolone antibiotics: properties of the class and individual agents. Clin. Ther. (1992) 14(3):348-375 (Discussion 347).
63. APPELBAUM PC, HUNTER PA: The fluoroquinolone antibacterials: past, present and future perspectives. Int. J Antimicrob. Agents (2000) 16(1):5-15.
64. BLONDEAU JM: Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option. Drugs (2004) 64(6):611-628.
65. TALAN DA, NABER KG, PALOU J, ELKHARRAT D: Extended-release ciprofloxacin (cipro XR) for treatment of urinary tract infections. Int. J. Antimicrob. Agents (2004) 23(Suppl. 1):S54-S66.
66. WAUGH J, KEATING GM: Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis. Drugs Aging (2004) 21(1):55-64.
67. SPIVEY JM, LAUGHLIN PH, GOSS TF, NIX DE: Theophylline toxicity secondary to ciprofloxacin administration. Ann. Emerg. Med. (1991) 20(10):1131-1134.
68. KOYLE MA, BARQAWI A, WILD J, PASSAMANECK M, FURNESS PD III: Pediatric urinary tract infections: the role of fluoroquinolones. Pediatr. Infect. Dis. J. (2003) 22(12):1133-1137.
69. KHALIQ Y, ZHANEL GG: Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin. Infect. Dis. (2003) 36(11):1404-1410.
70. CHOPRA N, FINE PL, PRICE B, ATLAS I: Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J. Urol. (2000) 164(2):438.
71. STEIGER D, BUBENDORF L, OBERHOLZER M, TAMM M, LEUPPI JD: Ciprofloxacin-induced acute interstitial pneumonitis. Eur. Respir. J. (2004) 23(1):172-174.
72. LETSAS KP, SIDERIS A, KOUNAS SP, EFREMIDIS M, KORANTZOPOULOS P, KARDARAS F: Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int. J. Cardiol. (2005) (In Press).
73. PRABHAKAR M, KRAHN AD: Ciprofloxacin-induced acquired long QT syndrome. Heart Rhythm (2004) 1(5):624-626.
74. SCHERER K, BIRCHER AJ: Hypersensitivity reactions to fluoroquinolones. Curr. Allergy Asthma Rep. (2005) 5(1):15-21.
75. MEAGHER AK, FORREST A, DALHOFF A, STASS H, SCHENTAG JJ: Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob. Agents Chemother. (2004) 48(6):2061-2068.
76. HENRY DC Jr, BETTIS RB, RIFFER E et al.: Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin. Ther. (2002) 24(12):2088-2104.
77. KLIMBERG I, SHOCKEY G, ELLISON H et al: Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study. Curr. Med. Res. Opin. (2005) 21(8):1241-1250.
78. NICKEL JC, LEE JC, GRANTMYRE JE, POLYGENIS D: Natural history of urinary tract infection in a primary care environment in Canada. Can. J. Urol. (2005) 12(4):2728-2737.